Pancreatic resection for M1 pancreatic ductal adenocarcinoma

Annals of Surgical Oncology

Volumn 14, Issue 1, 2007, Pages 118-127

  Shrikhande, Shailesh V ^a   Kleeff, Jörg ^b   Reiser, Carolin ^b   Weitz, Jürgen ^b   Hinz, Ulf ^b   Esposito, Irene ^b   Schmidt, Jan ^b   Friess, Helmut ^b   Büchler, Markus W ^b  

^a TATA MEMORIAL HOSPITAL   (India)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Interaortocaval lymph node metastasis; Liver metastasis; Metastatic disease; Pancreatic cancer; Resection; Survival

Indexed keywords

ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA BASE; FISHER EXACT TEST; HOSPITAL PATIENT; HUMAN; KAPLAN MEIER METHOD; LIVER METASTASIS; LIVER RESECTION; LOG RANK TEST; LYMPHADENECTOMY; METASTASIS; MORBIDITY; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS DUCT; PANCREAS RESECTION; PARAMETER; PERITONEUM METASTASIS; RETROSPECTIVE STUDY; SURVIVAL TIME;

ADENOCARCINOMA; AGED; CARCINOMA, PANCREATIC DUCTAL; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PANCREATECTOMY; PANCREATIC NEOPLASMS; SURVIVAL RATE;

EID: 33845648564     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-006-9131-8     Document Type: Article

References (52)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56:106-30
2. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001; 37(Suppl 8):S4-66
3. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94:153-6
4. Ozawa F, Friess H, Kunzli B, et al. Treatment of pancreatic cancer: the role of surgery. Dig Dis 2001; 19:47-56
5. Fernandez-del CC, Rattner DW, Warshaw AL. Standards for pancreatic resection in the 1990s. Arch Surg 1995; 130:295-9
6. Stojadinovic A, Hoos A, Brennan MF, Conlon KC. Randomized clinical trials in pancreatic cancer. Surg Oncol Clin N Am 2002; 11:207-29
7. Cameron JL, Pitt HA, Yeo CJ, Lillemoe KD, Kaufman HS, Coleman J. One hundred and forty-five consecutive pancreaticoduodenectomies without mortality. Ann Surg 1993; 217:430-5
8. Trede M, Schwall G, Saeger HD. Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality. Ann Surg 1990; 211:447-58
9. Howard JM. Development and progress in resective surgery for pancreatic cancer. World J Surg 1999; 23:901-6
10. Picozzi VJ, Kozarek RA, Traverso LW. Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg 2003; 185:476-80
11. Fortner JG. Regional pancreatectomy for cancer of the pancreas, ampulla, and other related sites. Tumor staging and results. Ann Surg 1984; 199:418-25
12. Fortner JG. "Radical" abdominal cancer surgery: current state and future course. Jpn J Surg 1989; 19:503-9
13. Shoup M, Conlon KC, Klimstra D, Brennan MF. Is extended resection for adenocarcinoma of the body or tail of the pancreas justified? J Gastrointest Surg 2003; 7:946-52
14. Yeo CJ, Cameron JL, Sohn TA, et al. Pancreaticoduodenectomy with or without extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma: comparison of morbidity and mortality and short-term outcome. Ann Surg 1999; 229:613-22
15. Capussotti L, Massucco P, Ribero D, Vigano L, Muratore A, Calgaro M. Extended lymphadenectomy and vein resection for pancreatic head cancer: outcomes and implications for therapy. Arch Surg 2003; 138:1316-22
16. Nguyen TC, Sohn TA, Cameron JL, et al. Standard vs. radical pancreaticoduodenectomy for periampullary adenocarcinoma: a prospective, randomized trial evaluating quality of life in pancreaticoduodenectomy survivors. J Gastrointest Surg 2003; 7:1-9
17. Pedrazzoli S, DiCarlo V, Dionigi R, et al. Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group. Ann Surg 1998; 228:508-17
18. Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality. Ann Surg 2002; 236:355-66
19. Van CE, Aerts R, Haustermans K, Topal B, Van SW, Verslype C. Systemic treatment of pancreatic cancer. Eur J Gastroenterol Hepatol 2004; 16:265-74
20. Smeenk HG, Tran TC, Erdmann J, van Eijck CH, Jeekel J. Survival after surgical management of pancreatic adenocarcinoma: does curative and radical surgery truly exist? Langenbecks Arch Surg 2005; 390:94-103
21. Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Buchler MW. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 2004; 91:586-94
22. Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas: 201 patients. Ann Surg 1995; 221:721-31
23. Neoptolemos JP, Stocken DD, Dunn JA, et al. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 2001; 234:758-68
24. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350:1200-10
25. Richter A, Niedergethmann M, Sturm JW, Lorenz D, Post S, Trede M. Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience. World J Surg 2003; 27:324-9
26. Bassi C, Stocken DD, Olah A, et al. Influence of surgical resection and post-operative complications on survival following adjuvant treatment for pancreatic cancer in the ESPAC-1 Randomized Controlled Trial. Dig Surg 2005; 22:353-63
27. Goldstein D, Carroll S, Apte M, Keogh G. Modern management of pancreatic carcinoma. Intern Med J 2004; 34:475-81
28. Koeppler H, Duru M, Grundheber M, et al. Palliative treatment of advanced pancreatic carcinoma in community-based oncology group practices. J Support Oncol 2004; 2:159-63
29. Prost P, Ychou M, Azria D. [Gemcitabine and pancreatic cancer]. Bull Cancer 2002; 89(Spec No):S91-5
30. Cunningham D, Chau I, Stocken D, et al. Phase III randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer. Eur J Cancer 2005; 3:4 (abstract PS11)
31. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib improves survival when added to gemcitabine in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). J Clin Oncol 2005;
32. ASCO Annual Meeting Proceedings. (abstract 77). Vol 23, No.16S, Part I of II (June 1 Supplement), 2005:1
33. 41st Annual Meeting American Society of Clinical Oncology (ASCO) May 13-17, 2005 Orlando, Florida
34. Yamada H, Katoh H, Kondo S, Okushiba S, Morikawa T. Hepatectomy for metastases from non-colorectal and non-neuroendocrine tumor. Anticancer Res 2001; 21:4159-62
35. Christophe M, Le Treut YP, Pol B, Brandone JM, Capobianco C, Bricot R. [Cancer of the pancreas. A plea for resection. 162 operated patients]. Presse Med 1992; 21:741-4
36. Lillemoe KD, Cameron JL, Yeo CJ, et al. Pancreaticoduodenectomy. Does it have a role in the palliation of pancreatic cancer? Ann Surg 1996; 223:718-25
37. Beger HG, Thorab FC, Liu Z, Harada N, Rau BM. Pathogenesis and treatment of neoplastic diseases of the papilla of Vater: Kausch-Whipple procedure with lymph node dissection in cancer of the papilla of Vater. J Hepatobiliary Pancreat Surg 2004; 11:232-8
38. Pedrazzoli S, Pasquali C, Sperti C. General aspects of surgical treatment of pancreatic cancer. Dig Surg 1999; 16:265-75
39. Shimada K, Kosuge T, Yamamoto J, Yamasaki S, Sakamoto M. Successful outcome after resection of pancreatic cancer with a solitary hepatic metastasis. Hepatogastroenterology 2004; 51:603-5
40. Sunada S, Miyata M, Tanaka Y, et al. Aggressive resection for advanced pancreatic carcinoma. Surg Today 1992; 22:74-7
41. Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15:2403-13
42. Conroy T, Paillot B, Francois E, et al. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer-a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. J Clin Oncol 2005; 23:1228-36
43. Van Cutsem E, van de Velde H, Karasek P, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004; 22:1430-8
44. Cress RD, Yin D, Clarke L, Bold R, Holly EA. Survival among patients with adenocarcinoma of the pancreas: a population-based study (United States). Cancer Causes Control 2006; 17:403-9
45. Carpelan-Holmstrom M, Nordling S, Pukkala E, et al. Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut 2005; 54:385-7
46. Connor S, Bosonnet L, Ghaneh P, et al. Survival of patients with periampullary carcinoma is predicted by lymph node 8a but not by lymph node 16b1 status. Br J Surg 2004; 91:1592-9
47. Farnell MB, Pearson RK, Sarr MG, et al. A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery 2005; 138:618-28
48. Henne-Bruns D, Vogel I, Luttges J, Kloppel G, Kremer B. Ductal adenocarcinoma of the pancreas head: survival after regional versus extended lymphadenectomy. Hepatogastroenterology 1998; 45:855-66
49. Nimura Y, Nagino M, Kato H, et al. Standard versus extended lymphadenectomy for pancreatic cancer: a multicenter, randomized controlled trial. Pancreatology 2004; 4:274
50. Klempnauer J, Ridder GJ, Piso P, Pichlmayr R. [Is liver resection in metastases of exocrine pancreatic carcinoma justified?]. Chirurg 1996; 67:366-70
51. Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005; 23:3509-16
52. Ueno H, Okusaka T, Ikeda M, Takezako Y, Morizane C. An early phase II study of S-1 in patients with metastatic pancreatic cancer. Oncology 2005; 68:171-8